Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Contributors and References

Contributors

R. S. Janssen, D. R. Holtgrave, and K. M. De Cock led the writing of this commentary. R. O. Valdiserri, M. Shepherd, and H. D. Gayle contributed ideas and helped with writing and reviewing the manuscript.

References

  1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2000;12(No.1):1-42.
  2. Rosenberg PS, Bigger RJ. Trends in HIV incidence among young adults in the United States. JAMA. 1998;279:1894-1899.
  3. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1999;48(RR-13):1-29.
  4. Anderson JE, Wilson RW, Barker P, Doll L, Jones TS, Holtgrave D. Prevalence of sexual and drug-related HIV risk behaviors in the US adult population: results of the 1996 National Household Survey on Drug Abuse. J Acquir Immune Defic Syndr. 1999;21:148-156.
  5. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. The living document: January 28, 2000.
  6. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Morb Mortal Wkly Rep. 1999;48(RR-10):1-59.
  7. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;113(suppl 1):97-106.
  8. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet. 2000;355:1158-1159.
  9. Justice AC, Chang CH, Fusco J, West N. Extrapolating long-term HIV/AIDS survival in the post-HAART era. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; September 26-29, 1999. Washington, DC: American Society for Microbiology; 1999. Abstract 1158:489.
  10. Martin JA, Smith BL, Mathews TJ, Ventura SJ. Births and deaths: preliminary data for 1998. Natl Vital Stat Rep. 1999;47(25):6-7.
  11. Wiktor SZ, Biggar RJ, Melbye M, et al. Effect of knowledge of human immunodeficiency virus infection status on sexual activity among homosexual men. J Acquir Immune Defic Syndr. 1990;3:62-68.
  12. Wenger NS, Kusseling FS, Beck K, Shapiro MF. Sexual behavior of individuals infected with the human immunodeficiency virus: the need for intervention. Arch Intern Med. 1994;154:1849-1854.
  13. Kilmarx PH, Hamers FF, Peterman TA. Living with HIV: experiences and perspectives of HIV-infected sexually transmitted disease clinic patients after posttest counseling. Sex Transm Dis. 1998;25:28-37.
  14. Higgins DL, Galavotti C, O'Reilly KR, et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA. 1991;266:2419-2429.
  15. Hays RB, Paul J, Ekstrand M, Kegeles SM, Stall R, Coates TJ. Actual versus perceived HIV status, sexual behaviors and predictors of unprotected sex among young gay and bisexual men who identify as HIV-negative, HIV-positive and untested. AIDS. 1997;11:1495-1502.
  16. Schaffer N, Roongpisuthipong A, Siriwasin W, et al. Maternal viral load and perinatal HIV-1 subtype E transmission, Bangkok, Thailand. J Infect Dis. 1999;179:590-599.
  17. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med. 1999;341:385-393.
  18. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med. 1999;341:394-402.
  19. Busch MP, Operskalski EA, Mosley JW, et al. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. J Infect Dis. 1996;174:26-33.
  20. Operskalski EA, Stram DO, Busch MP, et al. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Am J Epidemiol. 1997;146:655-661.
  21. Lee T-H, Sakahara N, Fiebig E, Busch MP, O'Brien TR, Herman SA. Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:427-428.
  22. Ragni MV, Faruki H, Kingsley LA. Heterosexual HIV-1 transmission and viral load in hemophilic patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:42-45.
  23. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921-929.
  24. Fideli U, Allen S, Musonda R, et al. Virologic determinants of heterosexual transmission in Africa. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; January 30-February 2, 2000. Alexandria, Va: Foundation for Retrovirology and Human Health; 2000. Abstract 194:111.
  25. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire. AIDS. 1997;11:F85-F93.
  26. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol. 1997;71:6271-6275.
  27. Vernazza PL, Gilliam BL, Dyer J, et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS. 1997;11:987-993.
  28. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS. 1997;11:1249-1254.
  29. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active anti-retroviral therapy. N Engl J Med. 1998;339:1803-1809.
  30. Miller CJ. Mucosal transmission of simian immunodeficiency virus. Curr Top Microbiol Immunol. 1994;188:107-122.
  31. Sodora DL, Gettie A, Miller CJ, Marx PA. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses. 1998;14(suppl 1):S119-S123.
  32. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
  33. Shaffer N, Chuachoowong R, Mock PA, et al. Short course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 1999;353:773-780.
  34. Morris A, Zorrilla C, Vajaranant M, et al. A review of protease inhibitor use in 89 pregnancies. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; Chicago, IL; January 31-February 4, 1999. Alexandria, Va: Foundation for Retrovirology and Human Health; 2000. Abstract 686:197.
  35. Peters V, Marinovich A, Singh T, Lindegren ML, Bertolli J, Thomas P. Trends to reduce perinatal HIV transmission in New York City. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; January 30-February 2, 2000. Alexandria, Va: Foundation for Retrovirology and Human Health; 2000. Abstract 707:207.
  36. May MR, Anderson RM. Transmission dynamics of HIV infection. Nature. 1987;326:137-142.
  37. Valdiserri RO, Holtgrave DR, West GR. Promoting early HIV diagnosis and entry into care. AIDS. 1999;13:2317-2330.
  38. Stetler HC, Granade RC, Nunez CA, et al. Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras. AIDS. 1997;11:369-375.
  39. Kassler WJ, Dillon GA, Haley C, et al. On-site, rapid HIV testing with same-day results and counseling. AIDS. 1997;11:1045-1051. [PsycINFO Link]
  40. Centers for Disease Control and Prevention. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings. MMWR Morb Mortal Wkly Rep. 1993;42(RR-2):1-6.
  41. Centers for Disease Control and Prevention. HIV counseling, testing, and referral guidelines. MMWR Morb Mortal Wkly Rep. In press.
  42. Osmond DH, Bindman AB, Vranizan K, et al. Name-based surveillance and public health interventions for persons with HIV infection. Ann Intern Med. 1999;131:775-779.
  43. Samet JH, Freedberg KA, Stein MD, et al. Trillion virion delay: time from testing positive for HIV to presentation for primary care. Arch Intern Med. 1998;158:734-740.
  44. HIV Prevention Strategic Plan Through 2005. Atlanta, Ga: Centers for Disease Control and Prevention; 2001.
  45. HIV Prevention Case Management: Guidance. Atlanta, Ga: Centers for Disease Control and Prevention; September 1997.
  46. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. N Engl J Med. 1998;339:1897-1904.
  47. Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; Chicago, IL; January 31-February 4, 1999. Alexandria, Va: Foundation for Retrovirology and Human Health; 2000. Abstract 92:84.
  48. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
  49. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-1141.
  50. Little SJ, Daar ES, D'Aquila, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999;282:1142-1149.
  51. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep. 1998;47(RR-20):1-51.
  52. Lehman JS, Hecht FM, Wortley P, Lansky A, Stevens M, Fleming P. Are at-risk populations less concerned about HIV infection in the HAART era? In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; January 30-February 2, 2000. Alexandria, Va: Foundation for Retrovirology and Human Health; 2000. Abstract 198:112.
  53. Centers for Disease Control and Prevention. Increases in unsafe sex and rectal gonorrhea among men who have sex with men-San Francisco, California, 1994-1997. MMWR Morb Mortal Wkly Rep. 1999;48:45-48.
  54. Marks G, Burris S, Peterman TA. Reducing sexual transmission of HIV from those who know they are infected: the need for personal and collective responsibility. AIDS. 1999;13:297-306.
  55. Centers for Disease Control and Prevention. Resurgent bacterial sexually transmitted disease among men who have sex with men-King County, Washington, 1997-1999. MMWR Morb Mortal Wkly Rep. 1999;48:773-777.
  56. Consensus Development Conference Statement: Interventions to Prevent HIV Risk Behaviors. Bethesda, Md: National Institutes of Health; February 11-13, 1997:1-41.
  57. Erbelding EJ, Stanton D, Quinn TC, Rompalo A. Behavioral and biologic evidence of persistent high-risk behavior in an HIV primary care population. AIDS. 2000;14:297-301.
  58. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr Hum Retrovirol. 1994;7:1169-1184.
  59. Janssen RS, Satten GA, Stramer L, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-48.
  60. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54-62.

Top of Page

 

Get Tested


Find an HIV testing site near you.

Search location, such as: "Atlanta, GA", or "30033".

For more information, please visit gettested.cdc.gov

Please contact GETTESTED-Webmaster@cdc.gov with any comments, suggestions, or concerns.


Syndicate This Content Podcast button Tell us what you think button CDC-INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO